TABLE 5.
Extra-ocular manifestations of BD and drug-related AEs before and after the treatment.
| Before treatment | After treatment | |||
|---|---|---|---|---|
| Main abnormality | CT (n = 24) | ADA (n = 21) | CT (n = 24) | ADA (n = 21) |
| Oral ulcer | 15 | 15 | 3 | 1 |
| Genital ulcer | 0 | 0 | 0 | 0 |
| Central nervous system symptoms | 0 | 0 | 0 | 0 |
| Vascular involvements | 0 | 0 | 0 | 0 |
| Skin erythema, rash or other skin changes | 3 | 3 | 4 | 2 |
| Articular symptoms | 3 | 0 | 0 | 1 |
| Upper respiratory infection or fever | 0 | 0 | 3 | 7 |
| Gastrointestinal symptoms | 0 | 0 | 0 | 2 |
| Hepatitis B | 0 | 0 | 1 | 0 |
| Tuberculosis | 0 | 0 | 1 | 0 |
| Pneumonia | 0 | 0 | 0 | 1 |
| Insomnia | 0 | 0 | 0 | 1 |
| Others | 0 | 0 | 2 | 0 |
Other skin changes including: In CT group, pox in 1 patient, alopecia in 1 patient and hydroxychloroquine-related skin change in 1 patient who suffered Hepatitis B; in ADA group, dermatophyte in 1 patient and alopecia in 1 patient. Glucocorticoid-related acne was not included in skin changes.
Other situations including: In CT group, 1 patient complained about growth retardation, and 1 patient complained about osteoporosis.